Copyright Reports & Markets. All rights reserved.

Global CNS Oral Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global CNS Oral Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Antidepressants
    • 1.3.3 Antipsychotics
    • 1.3.4 Anti-Dementia Drugs
    • 1.3.5 Anti-Parkinson's Drugs
    • 1.3.6 Antiepileptic Drugs
    • 1.3.7 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global CNS Oral Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Pharmacy
  • 1.5 Global CNS Oral Drugs Market Size & Forecast
    • 1.5.1 Global CNS Oral Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global CNS Oral Drugs Sales Quantity (2021-2032)
    • 1.5.3 Global CNS Oral Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer CNS Oral Drugs Product and Services
    • 2.1.4 Pfizer CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 Biogen
    • 2.2.1 Biogen Details
    • 2.2.2 Biogen Major Business
    • 2.2.3 Biogen CNS Oral Drugs Product and Services
    • 2.2.4 Biogen CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Biogen Recent Developments/Updates
  • 2.3 Otsuka
    • 2.3.1 Otsuka Details
    • 2.3.2 Otsuka Major Business
    • 2.3.3 Otsuka CNS Oral Drugs Product and Services
    • 2.3.4 Otsuka CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Otsuka Recent Developments/Updates
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis CNS Oral Drugs Product and Services
    • 2.4.4 Novartis CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments/Updates
  • 2.5 Teva Pharmaceutical
    • 2.5.1 Teva Pharmaceutical Details
    • 2.5.2 Teva Pharmaceutical Major Business
    • 2.5.3 Teva Pharmaceutical CNS Oral Drugs Product and Services
    • 2.5.4 Teva Pharmaceutical CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Teva Pharmaceutical Recent Developments/Updates
  • 2.6 Johnson & Johnson
    • 2.6.1 Johnson & Johnson Details
    • 2.6.2 Johnson & Johnson Major Business
    • 2.6.3 Johnson & Johnson CNS Oral Drugs Product and Services
    • 2.6.4 Johnson & Johnson CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Johnson & Johnson Recent Developments/Updates
  • 2.7 AstraZeneca
    • 2.7.1 AstraZeneca Details
    • 2.7.2 AstraZeneca Major Business
    • 2.7.3 AstraZeneca CNS Oral Drugs Product and Services
    • 2.7.4 AstraZeneca CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 AstraZeneca Recent Developments/Updates
  • 2.8 Merck
    • 2.8.1 Merck Details
    • 2.8.2 Merck Major Business
    • 2.8.3 Merck CNS Oral Drugs Product and Services
    • 2.8.4 Merck CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Merck Recent Developments/Updates
  • 2.9 GSK
    • 2.9.1 GSK Details
    • 2.9.2 GSK Major Business
    • 2.9.3 GSK CNS Oral Drugs Product and Services
    • 2.9.4 GSK CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 GSK Recent Developments/Updates
  • 2.10 Eli Lilly and Company
    • 2.10.1 Eli Lilly and Company Details
    • 2.10.2 Eli Lilly and Company Major Business
    • 2.10.3 Eli Lilly and Company CNS Oral Drugs Product and Services
    • 2.10.4 Eli Lilly and Company CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Eli Lilly and Company Recent Developments/Updates
  • 2.11 Lundbeck
    • 2.11.1 Lundbeck Details
    • 2.11.2 Lundbeck Major Business
    • 2.11.3 Lundbeck CNS Oral Drugs Product and Services
    • 2.11.4 Lundbeck CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Lundbeck Recent Developments/Updates
  • 2.12 Takeda
    • 2.12.1 Takeda Details
    • 2.12.2 Takeda Major Business
    • 2.12.3 Takeda CNS Oral Drugs Product and Services
    • 2.12.4 Takeda CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Takeda Recent Developments/Updates
  • 2.13 Bristol Myers Squibb
    • 2.13.1 Bristol Myers Squibb Details
    • 2.13.2 Bristol Myers Squibb Major Business
    • 2.13.3 Bristol Myers Squibb CNS Oral Drugs Product and Services
    • 2.13.4 Bristol Myers Squibb CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Bristol Myers Squibb Recent Developments/Updates
  • 2.14 Jiangsu Nhwa Pharmaceutical
    • 2.14.1 Jiangsu Nhwa Pharmaceutical Details
    • 2.14.2 Jiangsu Nhwa Pharmaceutical Major Business
    • 2.14.3 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Product and Services
    • 2.14.4 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Jiangsu Nhwa Pharmaceutical Recent Developments/Updates
  • 2.15 Luye Pharma
    • 2.15.1 Luye Pharma Details
    • 2.15.2 Luye Pharma Major Business
    • 2.15.3 Luye Pharma CNS Oral Drugs Product and Services
    • 2.15.4 Luye Pharma CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Luye Pharma Recent Developments/Updates
  • 2.16 Zhejiang Huahai Pharmaceutical
    • 2.16.1 Zhejiang Huahai Pharmaceutical Details
    • 2.16.2 Zhejiang Huahai Pharmaceutical Major Business
    • 2.16.3 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Product and Services
    • 2.16.4 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Zhejiang Huahai Pharmaceutical Recent Developments/Updates
  • 2.17 Chengdu Easton Biopharmaceuticals
    • 2.17.1 Chengdu Easton Biopharmaceuticals Details
    • 2.17.2 Chengdu Easton Biopharmaceuticals Major Business
    • 2.17.3 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Product and Services
    • 2.17.4 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Chengdu Easton Biopharmaceuticals Recent Developments/Updates
  • 2.18 Hansoh Pharmaceutical
    • 2.18.1 Hansoh Pharmaceutical Details
    • 2.18.2 Hansoh Pharmaceutical Major Business
    • 2.18.3 Hansoh Pharmaceutical CNS Oral Drugs Product and Services
    • 2.18.4 Hansoh Pharmaceutical CNS Oral Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Hansoh Pharmaceutical Recent Developments/Updates

3 Competitive Environment: CNS Oral Drugs by Manufacturer

  • 3.1 Global CNS Oral Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global CNS Oral Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global CNS Oral Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of CNS Oral Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 CNS Oral Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 CNS Oral Drugs Manufacturer Market Share in 2025
  • 3.5 CNS Oral Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 CNS Oral Drugs Market: Region Footprint
    • 3.5.2 CNS Oral Drugs Market: Company Product Type Footprint
    • 3.5.3 CNS Oral Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global CNS Oral Drugs Market Size by Region
    • 4.1.1 Global CNS Oral Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global CNS Oral Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global CNS Oral Drugs Average Price by Region (2021-2032)
  • 4.2 North America CNS Oral Drugs Consumption Value (2021-2032)
  • 4.3 Europe CNS Oral Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific CNS Oral Drugs Consumption Value (2021-2032)
  • 4.5 South America CNS Oral Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa CNS Oral Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global CNS Oral Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global CNS Oral Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global CNS Oral Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global CNS Oral Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global CNS Oral Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global CNS Oral Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America CNS Oral Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America CNS Oral Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America CNS Oral Drugs Market Size by Country
    • 7.3.1 North America CNS Oral Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America CNS Oral Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe CNS Oral Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe CNS Oral Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe CNS Oral Drugs Market Size by Country
    • 8.3.1 Europe CNS Oral Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe CNS Oral Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific CNS Oral Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific CNS Oral Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific CNS Oral Drugs Market Size by Region
    • 9.3.1 Asia-Pacific CNS Oral Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific CNS Oral Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America CNS Oral Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America CNS Oral Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America CNS Oral Drugs Market Size by Country
    • 10.3.1 South America CNS Oral Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America CNS Oral Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa CNS Oral Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa CNS Oral Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa CNS Oral Drugs Market Size by Country
    • 11.3.1 Middle East & Africa CNS Oral Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa CNS Oral Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 CNS Oral Drugs Market Drivers
  • 12.2 CNS Oral Drugs Market Restraints
  • 12.3 CNS Oral Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of CNS Oral Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of CNS Oral Drugs
  • 13.3 CNS Oral Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 CNS Oral Drugs Typical Distributors
  • 14.3 CNS Oral Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global CNS Oral Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global CNS Oral Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global CNS Oral Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global CNS Oral Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global CNS Oral Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global CNS Oral Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for CNS Oral Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global CNS Oral Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Biogen, Otsuka, Novartis, Teva Pharmaceutical, Johnson & Johnson, AstraZeneca, Merck, GSK, Eli Lilly and Company, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    CNS Oral Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Antidepressants
    Antipsychotics
    Anti-Dementia Drugs
    Anti-Parkinson's Drugs
    Antiepileptic Drugs
    Others
    Market segment by Application
    Hospital and Clinic
    Pharmacy
    Major players covered
    Pfizer
    Biogen
    Otsuka
    Novartis
    Teva Pharmaceutical
    Johnson & Johnson
    AstraZeneca
    Merck
    GSK
    Eli Lilly and Company
    Lundbeck
    Takeda
    Bristol Myers Squibb
    Jiangsu Nhwa Pharmaceutical
    Luye Pharma
    Zhejiang Huahai Pharmaceutical
    Chengdu Easton Biopharmaceuticals
    Hansoh Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe CNS Oral Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of CNS Oral Drugs, with price, sales quantity, revenue, and global market share of CNS Oral Drugs from 2021 to 2026.
    Chapter 3, the CNS Oral Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the CNS Oral Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and CNS Oral Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of CNS Oral Drugs.
    Chapter 14 and 15, to describe CNS Oral Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now